Zobrazeno 1 - 10
of 111
pro vyhledávání: ''
Autor:
Nilay Shah, Lindsey R. Sangaralingham, Parambir S. Dulai, Herbert C. Heien, William J. Sandborn, Jeph Herrin, Siddharth Singh
Publikováno v:
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, vol 20, iss 2
Clin Gastroenterol Hepatol
Clin Gastroenterol Hepatol
Background and Aims We conducted a retrospective cohort study comparing the risk of serious infections between patients treated with tumor necrosis factor-a (TNFa) antagonists vs. vedolizumab in patients with inflammatory bowel diseases (IBD). Method
Autor:
Yiran Zhang, Satimai Aniwan, A Weiss, Gursimran Kochhar, Sunanda V. Kane, Bo Shen, Matthew Bohm, Siddharth Singh, Eugenia Shmidt, Jean-Frederic Colombel, Corey A. Siegel, David Faleck, Edward V. Loftus, James P. Campbell, Mahmoud A. Rahal, Siri Kadire, Ronghui Xu, William J. Sandborn, David Hudesman, Arun Swaminath, Joseph Meserve, Robert Hirten, Vipul Jairath, Ryan C. Ungaro, Bruce E. Sands, Karen Lasch, Jenna L. Koliani-Pace, Brigid S. Boland, Parambir S. Dulai, Dana J. Lukin, Shreya Chablaney, Monika Fischer, Adam Winters, Gloria Tran, Shannon Chang, Sashidhar Varma
Publikováno v:
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, vol 20, iss 1
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, vol 20, iss 1
Background & Aims We aimed to compare safety and effectiveness of vedolizumab to tumor necrosis factor (TNF)-antagonist therapy in ulcerative colitis in routine practice. Methods A multicenter, retrospective, observational cohort study (May 2014 to D
Autor:
Jordan C. Pruce, Jessica R. Allegretti, Rahul S. Dalal, Jenna Marcus, Scott Esckilsen, Edward L. Barnes
Publikováno v:
Clinical Gastroenterology and Hepatology. 20:2399-2401.e4
Ustekinumab has been shown to be effective for the treatment of ulcerative colitis (UC); however, >40% of patients have suboptimal clinical response after induction and maintenance dosing every 8 weeks.1,2 The best management approach for these patie
Autor:
Emily C L Wong, Parambir S. Dulai, Jean-Frederic Colombel, John Marshall, Neeraj Narula, Walter Reinisch
Publikováno v:
Clinical Gastroenterology and Hepatology. 20:1588-1597.e3
Background & Aims Comparative effectiveness studies are needed to help position therapies for ulcerative colitis (UC). We compared the efficacy of infliximab vs vedolizumab for moderate to severe biologic-naive UC using patient-level data from clinic
Autor:
Evan S. Dellon, Margaret H. Collins, David A. Katzka, Vincent A. Mukkada, Gary W. Falk, Robin Morey, Bridgett Goodwin, Jessica D. Eisner, Lan Lan, Nirav K. Desai, James Williams, Ikuo Hirano, Curtis Baum, Pradeep Bekal, David Chaletsky, Mirna Chehade, Larry Clark, Evan Dellon, Reed Dimmitt, David Dulitz, Gary Falk, Ronald Fogel, Keith Friedenberg, Scott Gabbard, Andrew Gentry, Benjamin Gold, Michael Goldstein, Sandeep Gupta, Karen Hsu-Blatman, Vikram Jayanty, David Katzka, Vidhya Kunnathur, John Lee, John Leung, Jonathan Markowitz, Calies Menard-Katcher, Benjamin Mitlyng, Sam E. Moussa, Vincent Mukkada, Molly O’Gorman, Juan Olazagasti, Timothy Ritter, Wael Sayej, Shauna Schroeder, Yamen Smadi, Daniel Soteres, Theodore Stathos, Michael F. Vaezi, Tom Whitlock, John Wo, Ziad Younes, Salam Zakko
Publikováno v:
Clinical Gastroenterology and Hepatology. 20:1488-1498.e11
BACKGROUND & AIMS We evaluated treatment withdrawal, long-term outcomes, and safety of budesonide oral suspension (BOS) 2.0 mg twice daily in patients with eosinophilic esophagitis who completed a 12-week induction study. METHODS Induction full respo
Autor:
Xiaoying Huang, Xiaofei Li
Publikováno v:
Clinical Gastroenterology and Hepatology. 20:e1216
Autor:
Christopher Gasink, Subrata Ghosh, Rory Rebuck, Bruce E. Sands, Omoniyi J. Adedokun, John P. Lynch, Jean-Frederic Colombel, William J. Sandborn, Bin Zou, Stephen B. Hanauer, Willem J.S. de Villiers, Brian G. Feagan, Stephan R. Targan, Yuhua Wang
Publikováno v:
Clin Gastroenterol Hepatol
Background & Aims The IM-UNITI study and long-term extension (LTE) evaluated the long-term efficacy, safety, and immunogenicity of subcutaneous ustekinumab maintenance therapy in patients with Crohn’s disease. Here, we report the final results of I
Autor:
Nirav K. Desai, Evan S. Dellon, Vincent A. Mukkada, Robin Morey, David A. Katzka, Ikuo Hirano, Margaret H. Collins, James Williams, Gary W. Falk, Lan Lan
Publikováno v:
Clinical Gastroenterology and Hepatology. 20:525-534.e10
BACKGROUND & AIMS Eosinophilic esophagitis (EoE) is a chronic, immune-mediated disease for which there is currently no pharmacologic therapy approved by the US Food and Drug Administration. METHODS In this double-blind, placebo-controlled, phase 3 tr
Autor:
Santhi Swaroop Vege, Michael J. Levy, Mark Topazian, Randall K. Pearson, Shounak Majumder, Ryan J. Lennon, Suresh T. Chari, Bret T. Petersen, Guilherme Piovezani Ramos, Neil Postier, Ferga C. Gleeson, Sonmoon Mohapatra, Thomas E. Witzig
Publikováno v:
Clinical Gastroenterology and Hepatology. 16:1947-1953
Background & Aims IgG4–related disease (IgG4-RD), a multi-organ fibroinflammatory syndrome, typically responds to steroids. However, some cases are steroid resistant, and pancreaticobiliary IgG4-RD commonly relapses after steroid withdrawal. Rituxi
Autor:
Carlo Di Lorenzo, Taryn Losch-Beridon, Molly O'Gorman, Sunny Z. Hussain, Marc A. Benninga, Samuel Nurko, Shadreck M. Mareya, Peter Lichtlen, Manu R. Sood, Robert A. Clifford, Paul E. Hyman
Publikováno v:
Clinical gastroenterology and hepatology. W.B. Saunders Ltd
Background & Aims Pediatric functional constipation (PFC) is a common problem in children that causes distress and presents treatment challenges to health care professionals. We conducted a randomized, placebo-controlled trial (study 1) in patients w